haemophilia B

News

Trial sets up filings for uniQure's haemophilia gene therapy

Dutch biotech uniQure and partner CSL Behring are planning to file for approval of their gene therapy for haemophilia B, armed with new trial data that they say answers earlier concerns abo

News

Sanofi eyes 2022 filing for haemophilia drug fitusiran, desp...

Sanofi's much anticipated drug for both haemophilia A and B – fitusiran – could be filed in 2022 despite a problem with blood clots in some patients in late-stage testing.

News

FDA lifts hold on uniQure gene therapy after cancer case rev...

Dosing can start once again in uniQure's phase 3 trial of its haemophilia B gene therapy, after the FDA concluded that a case of liver cancer seen in the study was unlikely to be caused by

News

$2bn deal sees uniQure license haemophilia B gene therapy to...

UniQure has signed a deal that could be worth over $2 billion with CSL Behring – giving the company exclusive global rights to uniQure’s gene therapy for haemophilia B.

R&D

Pfizer moves haemophilia gene therapy into phase 3

US pharma giant Pfizer and partner Spark Therapeutics has begun a phase 3 trial of a gene therapy for patients with haemophilia B, which could see an end to patients needing constant inject

News

Spark/Pfizer eye phase 3 trial of haemophilia B gene therapy

Spark Therapeutics has already revolutionised treatment of a rare hereditary eye disease with a gene therapy, but could it be about to do the same with haemophilia B?

Trial sets up filings for uniQure's haemophilia gene therapy

Sanofi eyes 2022 filing for haemophilia drug fitusiran, desp...

FDA lifts hold on uniQure gene therapy after cancer case rev...

$2bn deal sees uniQure license haemophilia B gene therapy to...

Pfizer moves haemophilia gene therapy into phase 3

Spark/Pfizer eye phase 3 trial of haemophilia B gene therapy

CEPI steps in to fund Moderna's pandemic flu jab

How to meet your physicians where they are online

haemophilia B

Editor's Picks